A randomised controlled trial of high versus low long chain triglyceride whole protein feed in active Crohn's disease

被引:46
|
作者
Leiper, K
Woolner, J
Mullan, MMC
Parker, T
van der Vliet, M
Fear, S
Rhodes, JM
Hunter, JO
机构
[1] Univ Liverpool, Dept Med, Gastroenterol Res Grp, Liverpool L69 3GA, Merseyside, England
[2] Addenbrookes Hosp, Dept Gastroenterol, Cambridge CB2 2QQ, England
[3] Int Ctr Lung Canc Res, Liverpool, Merseyside, England
关键词
Crohn's disease therapy; polymeric feeds; dietary fat;
D O I
10.1136/gut.49.6.790
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background-Polymeric feeds have shown variable efficacy in active Crohn's disease (CD) with remission rates from 36% to 82%. Meta-analyses of elemental, peptide, and whole protein feeds have shown a strong negative correlation between remission rate in CD and the long chain triglyceride (LCT) content of the feed. We performed a randomised controlled double blind trial in patients with active CD comparing two single whole protein feeds with LCT supplying 5% or 30% of the total energy. Methods-Fifty four patients with active CD (Crohn's disease activity index (CDAI) > 200, serum C reactive protein (CRP) 10 mg/1) were randomised to a high or low LCT feed for three weeks. The total amount of energy supplied by fat was identical in the two feeds. Remission was defined as a CDAI less than or equal to 150 and response as a fall in CDAI of greater than or equal to 70 or a CRP < 10 mg/l. Results-Overall remission rate by intention to treat was 26% for the low LCT feed and 33% for the high LCT feed (p=0.38). Response was achieved in 33% with the low LCT and in 52% with the high LCT feed (p=0.27). CRP < 10 mg/l was achieved in 30% in the low LCT and 33% in the high LCT group (p=0.99). Thirty nine per cent (21/54) of patients withdrew before three weeks because of inability to tolerate the diet. Excluding patients unable to tolerate the diet, remission rates were 46% for low LCT and 45% for high LCT (p=0.99). Discussion-This trial has shown no difference in the effect of low and high LCT whole protein feeds in active CD. The previously reported correlation between LCT content of diet and response in active CD is unlikely to be due to LCT itself and may be due to some other component of high LCT feeds.
引用
收藏
页码:790 / 794
页数:5
相关论文
共 50 条
  • [42] Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: A randomized controlled open-label trial
    Borrelli, Osvaldo
    Cordischi, Letizia
    Cirulli, Manuela
    Paganelli, Massimiliano
    Labalestra, Valeria
    Uccini, Stefania
    Russo, Paolo M.
    Cucchiara, Salvatore
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (06) : 744 - 753
  • [43] Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease
    Herllinger, KR
    Witthoeft, T
    Raedler, A
    Bokemeyer, B
    Krummenerl, T
    Schulzke, JD
    Boerner, N
    Kueppers, B
    Emmrich, J
    Mescheder, A
    Schwertschlag, U
    Shapiro, M
    Stange, EF
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (04): : 793 - 797
  • [44] Clinically active Crohn's disease in the presence of a low C-reactive protein
    Florin, THJ
    Paterson, EWJ
    Fowler, EV
    Radford-Smith, GL
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2006, 41 (03) : 306 - 311
  • [45] CROHN'S DISEASE STRICTURES RESPOND TO ADALIMUMAB DRUG TREATMENT. LONG TERM (4.5 YEARS) RESULTS OF THE STRIDENT RANDOMISED CONTROLLED TRIAL
    Lovett, Grace C.
    Schulberg, Julien D.
    Hamilton, Amy L.
    Wright, Emily K.
    Holt, Bronte A.
    Sutherland, Tom
    Ross, Alyson L.
    Kamm, Michael A.
    GASTROENTEROLOGY, 2024, 166 (05) : S809 - S809
  • [46] Effect of communicating DNA based risk assessments for Crohn's disease on smoking cessation: randomised controlled trial
    Hollands, Gareth J.
    Whitwell, Sophia C. L.
    Parker, Richard A.
    Prescott, Natalie J.
    Forbes, Alastair
    Sanderson, Jeremy
    Mathew, Christopher G.
    Lewis, Cathryn M.
    Watts, Sally
    Sutton, Stephen
    Armstrong, David
    Kinmonth, Ann Louise
    Prevost, A. Toby
    Marteau, Theresa M.
    BMJ-BRITISH MEDICAL JOURNAL, 2012, 345
  • [47] Crohn's disease therapeutic dietary intervention (CD-TDI): study protocol for a randomised controlled trial
    Raman, Maitreyi
    Ma, Christopher
    Taylor, Lorian M.
    Dieleman, Levinus A.
    Gkoutos, Georgios, V
    Vallance, Jeff K.
    McCoy, Kathy D.
    Lewis, Ian
    Jijon, Humberto
    McKay, Derek M.
    Mutch, David M.
    Barkema, Herman W.
    Gibson, Deanna
    Rauch, Marcus
    Ghosh, Subrata
    BMJ OPEN GASTROENTEROLOGY, 2022, 9 (01):
  • [48] Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
    Colombel, Jean-Frederic
    Panaccione, Remo
    Bossuyt, Peter
    Lukas, Milan
    Baert, Filip
    Vanasek, Tomas
    Danalioglu, Ahmet
    Novacek, Gottfried
    Armuzzi, Alessandro
    Hebuterne, Xavier
    Travis, Simon
    Danese, Silvio
    Reinisch, Walter
    Sandborn, William J.
    Rutgeerts, Paul
    Hommes, Daniel
    Schreiber, Stefan
    Neimark, Ezequiel
    Huang, Bidan
    Zhou, Qian
    Mendez, Paloma
    Petersson, Joel
    Wallace, Kori
    Robinson, Anne M.
    Thakkar, Roopal B.
    D'Haens, Geert
    LANCET, 2017, 390 (10114): : 2779 - 2789
  • [49] A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease
    Dotan, Iris
    Rachmilewitz, Daniel
    Schreiber, Stefan
    Eliakim, Rami
    van der Woude, C. Janneke
    Kornbluth, Asher
    Buchman, Alan L.
    Bar-Meir, Shimon
    Bokemeyer, Bernd
    Goldin, Eran
    Maaser, Christian
    Mahadevan, Uma
    Seidler, Ursula
    Hoffman, Joerg C.
    Homoky, Douglas
    Plasse, Terry
    Powers, Barbara
    Rutgeerts, Paul
    Hommes, Daniel
    GUT, 2010, 59 (06) : 760 - 766
  • [50] Randomised double-blind placebo-controlled trial of recombinant humanised antibody to α4 integrin (Antegren™) in active Crohn's disease.
    Gordon, FH
    Lai, CWY
    Hamilton, MI
    Allison, MC
    Fouweather, M
    Donoghue, S
    Greenless, C
    Amlot, PL
    Srivastava, ED
    Subhani, J
    Pounder, RE
    GASTROENTEROLOGY, 1999, 116 (04) : A726 - A726